WallStreetZenWallStreetZen

NASDAQ: NERV
Minerva Neurosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NERV stock forecasts and price targets.

Forecast return on equity

Is NERV forecast to generate an efficient return?

Company
0%
Industry
113.08%
Market
338.14%
NERV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NERV forecast to generate an efficient return on assets?

Company
0%
Industry
32.96%
NERV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NERV earnings per share forecast

What is NERV's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.73-284.7%
Avg 2 year Forecast
-$1.92-229.57%
Avg 3 year Forecast
$0.00-100%

NERV revenue forecast

What is NERV's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$57.6M

NERV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NERV$3.82N/AN/A
INTS$0.57$2.25+294.74%Strong Buy
BTAI$1.86$26.67+1,333.71%Buy
LNAI$1.17N/AN/A
RLYB$0.63N/AN/A
View Top Biotech Stocks

Minerva Neurosciences Stock Forecast FAQ

What is NERV's earnings growth forecast for 2025-2027?

(NASDAQ: NERV) Minerva Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 55.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.85%.

Minerva Neurosciences's earnings in 2025 is $11,229,597.On average, 3 Wall Street analysts forecast NERV's earnings for 2025 to be -$19,117,175, with the lowest NERV earnings forecast at -$18,367,482, and the highest NERV earnings forecast at -$19,679,444. On average, 3 Wall Street analysts forecast NERV's earnings for 2026 to be -$13,410,555, with the lowest NERV earnings forecast at -$12,884,651, and the highest NERV earnings forecast at -$13,804,983.

In 2027, NERV is forecast to generate $0 in earnings, with the lowest earnings forecast at $0 and the highest earnings forecast at $0.

If you're new to stock investing, here's how to buy Minerva Neurosciences stock.

What is NERV's revenue growth forecast for 2025-2027?

(NASDAQ: NERV) Minerva Neurosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 294.78%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.91%.

Minerva Neurosciences's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast NERV's revenue for 2025 to be $0, with the lowest NERV revenue forecast at $0, and the highest NERV revenue forecast at $0. On average, 3 Wall Street analysts forecast NERV's revenue for 2026 to be $0, with the lowest NERV revenue forecast at $0, and the highest NERV revenue forecast at $0.

In 2027, NERV is forecast to generate $402,974,041 in revenue, with the lowest revenue forecast at $387,168,943 and the highest revenue forecast at $414,827,864.

What is NERV's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: NERV) forecast ROA is 0%, which is lower than the forecast US Biotechnology industry average of 32.96%.

What is NERV's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NERV) Minerva Neurosciences's current Earnings Per Share (EPS) is $1.48. On average, analysts forecast that NERV's EPS will be -$2.73 for 2025, with the lowest EPS forecast at -$2.63, and the highest EPS forecast at -$2.81. On average, analysts forecast that NERV's EPS will be -$1.92 for 2026, with the lowest EPS forecast at -$1.84, and the highest EPS forecast at -$1.97. In 2027, NERV's EPS is forecast to hit $0.00 (min: $0.00, max: $0.00).

What is NERV's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: NERV) forecast ROE is 0%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.